Briefs: Neuland Laboratories and Granules India
Granules India receives 1 observation from USFDA for Chantilly facility
Granules India receives 1 observation from USFDA for Chantilly facility
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
Ranks among the top 15% companies globally
Dilip Shanghvi to continue as the Executive Chairman of the Board
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Subscribe To Our Newsletter & Stay Updated